GlobalData on MSN

CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension

CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
BioWorld

Items Tagged with 'beta2-adrenergic receptor agonist'

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
ascopubs.org

Association between β3-adrenergic receptor agonist use and risk of kidney cancer among patients with overactive bladder.

Prognostic value of circulating tumor DNA fraction (TF) for patients with metastatic renal cell carcinoma (mRCC). Effect of cytoreductive nephrectomy on the efficacy of immunotherapy in metastatic ...

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in ...
Medical News Today

Chronic pain: Non-opioid drug candidates could offer relief without addiction

Share on Pinterest A recent study used computational methods to identify novel compounds that activate receptors involved in pain modulation without sedation. Peter Dazeley/Getty Images Research on ...
Pharmabiz

US FDA approves Viatris & Ocuphire Pharma’s Ryzumvl 0.75% eye drops to treat pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents

Viatris Inc., a global healthcare company, and Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved ...